Elevance Health Inc. ($ELV) Stock Forecast: Up 5.4% Today

What is Elevance Health Inc.?

Elevance Health Inc. (ELV) is a health insurer facing challenges in its operating revenue and profitability due to margin and volume pressures. Despite beating profit expectations, the company missed revenue targets and issued a soft outlook for fiscal year 2026.

Why is Elevance Health Inc. going up?

ELV stock is up 5.4% on Jan 28, 2026 20:15

• Elevance Health (ELV) saw a strong bullish movement following a positive reaction to surpassing profit expectations for Q4 2025.
• Despite a mix of results with profits exceeding expectations but revenues falling short investor confidence surged as the company focuses on affordability and platform enhancements.
• Analysts and investors found reassurance in the company's ability to outperform profit expectations and maintain a positive earnings per share outlook for 2026 amidst revenue growth challenges and margin pressures.
• The market shift may have been influenced by general sentiment towards the healthcare and insurance sectors, weighing concerns about margin risks and membership attrition against the company's profit beat and earnings forecast.

ELV Price Chart

ELV Technical Analysis

ELV News

Elevance Health Q4 Earnings Review: No Sign Of An End To The Pain (NYSE:ELV)

Elevance Health, Inc. (ELV) is facing significant margin and volume pressures, with its Q4 operating revenue down 55% year-over-year and weak guidance for 2026. The company's benefit expense ratio remains high at 90% due to medical inflation and increased utilization, impacting profitability. Analyst maintains a Hold rating on ELV, citing weak guidance, sector headwinds, and a lack of near-term catalysts for margin recovery.

https://seekingalpha.com/article/4863371-elevance-health-q4-earnings-review-no-sign-of-an-end-to-pain

US Health Insurer Elevance Health Issues Soft Outlook, Lower Premium Forecast For 2026

Elevance Health (NYSE:ELV) reported mixed Q4 2025 earnings with revenues below consensus but adjusted EPS beating estimates. The health insurer also issued a soft outlook for fiscal year 2026, forecasting lower premium growth and a decline in Medicare Advantage and Medicaid memberships. Concerns were also raised regarding the Centers for Medicare & Medicaid Services' proposed payment rates for 2027, which do not align with current medical cost trends.

https://www.benzinga.com/markets/earnings/26/01/50192293/us-health-insurer-elevance-health-issues-soft-outlook-lower-premium-forecast-for-2026

Insurers Brace For Extended 'Managed Retreat' Following 2027 MA Proposal (NYSEARCA:IHF)

The CMS's 2027 Medicare Advantage rate proposal, with a mere 0.09% average revenue update, poses significant margin risks for UnitedHealth and other managed care insurers. This shortfall, well below medical cost trends, is expected to pressure profitability and benefit funding, leading to a negative sentiment for the sector. The IHF ETF is particularly vulnerable due to its heavy concentration in managed care, and insurers are likely to prioritize margin defense over membership growth until the final CMS announcement in April 2026.

https://seekingalpha.com/article/4863331-insurers-brace-for-extended-managed-retreat-following-2027-ma-proposal?source=google_editors_picks

Elevance Health beats on profit, misses on revenue in mixed Q4

Elevance Health reported mixed results for Q4 2025, beating profit expectations with $547 million but missing revenue targets at $49.3 billion. Despite a nearly 10% year-over-year revenue growth and strong full-year revenue of $197.6 billion, profits were down compared to 2024, and the company faced elevated medical loss ratios and Medicaid membership attrition. For 2026, Elevance Health anticipates at least $25.50 in earnings per share and a slight revenue decline, focusing on affordability and strengthening its diversified platform.

https://www.fiercehealthcare.com/payers/elevance-health-beats-profit-misses-revenue-mixed-q4

Elevance Health: Q4 Earnings Snapshot

Elevance Health Inc. reported Q4 earnings of $547 million, or $2.47 per share, with adjusted earnings of $3.33 per share, surpassing analyst expectations. The health insurer posted revenue of $49.75 billion, though its adjusted revenue of $49.31 billion missed Street forecasts. For the full year, the company had a profit of $5.66 billion on revenue of $197.58 billion and expects full-year earnings of $25.50 per share.

https://www.kare11.com/article/syndication/associatedpress/elevance-health-q4-earnings-snapshot/616-2b328367-36a8-46ef-a5f5-e7651c2897a8

Trending Today

Dash ($DASH) Crypto Forecast: Down 8.1% Today

ZCash ($ZEC) Crypto Forecast: Down 6.5% Today

Worldcoin ($WLD) Crypto Forecast: Up 14.0% Today

Gold ($XAU) Commodity Forecast: Up 6.4% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Microchip Technology Incorporated ($MCHP) Stock Forecast: Up 6.3% Today

Corning Incorporated ($GLW) Stock Forecast: Down 5.2% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 9.5% Today

Sunrun Inc. ($RUN) Stock Forecast: Up 5.1% Today

Elevance Health Inc. ($ELV) Stock Forecast: Up 5.4% Today

Elevance Health Inc. Price History

05.00.2026 - ELV Stock was up 1.3%

• ELV stock saw a positive movement today, possibly influenced by favorable updates regarding its collaboration with American Well.
• The extension of the partnership with American Well under new three-year agreements represents a significant benefit for ELV, signaling continued growth potential in digital healthcare.
• The robust Q3 earnings results, surpassing expectations with strong EPS and revenue numbers, also played a role in the positive market sentiment towards Elevance Health.
• In summary, the mix of enhanced partnership agreements and impressive financial performance likely boosted investor confidence in ELV, resulting in the upward movement in the market.

31.09.2025 - ELV Stock was down 5.1%

• The surge in implied volatility for Elevance Health stock options indicates increased uncertainty and potential downside risk perceived by investors.
• The heightened options activity could suggest speculation or hedging strategies being implemented by market participants, reflecting a lack of confidence in ELV's short-term outlook.
• The overall bearish movement in ELV's stock price today might be attributed to the escalating concerns and cautious sentiment among investors, as reflected in the options market activity.

27.00.2026 - ELV Stock was down 8.1%

• Vanguard Personalized Indexing Management LLC and Barlow Wealth Partners Inc. notably decreased their holdings in Elevance Health, aligning with the downward market trend.
• A proposed flat Medicare Advantage payment rate increase by the Trump administration for 2027, falling short of expectations, has impacted Elevance Health and other major health insurers, leading to a decline in stock value.
• While some institutional investors like Whittier Trust Co. divested their shares, Norges Bank and Vanguard Group increased their positions, reflecting mixed investor sentiment.
• The regulatory announcement's potential effects on Humana and other insurers have added to the negative market sentiment in the healthcare sector and influenced Elevance Health's stock performance.

27.00.2026 - ELV Stock was down 12.4%

• The bearish movement in ELV's stock can be attributed to the proposed flat rates for Medicare Advantage plans by the government, impacting major health insurers.
• Recent decisions by health insurers to adjust Medicare Advantage benefits and underwhelming Q4 performance reports have contributed to negative sentiment in the sector.
• Institutional investors have shown varying stances on ELV, with some reducing their stake while others increasing their position.
• The regulatory announcement regarding Medicare payment rate increases for 2027 has put pressure on healthcare companies reliant on Medicare Advantage plans, leading to a bearish trend in ELV's stock price.

27.00.2026 - ELV Stock was down 14.2%

• Elevance Health (ELV) experienced a strong bearish movement likely due to the broader sector-wide selloff following proposed changes in Medicare Advantage payment rates for 2027.
• The reduction in Medicare Advantage benefits by other companies, in response to disappointing reimbursement rates, further added to the negative sentiment surrounding healthcare stocks, including ELV.
• A reduction in stake by an institutional investor in Elevance Health could have also contributed to the downward pressure on the stock, signaling decreased institutional confidence in the company amidst regulatory uncertainty and market volatility.
• The upcoming earnings report of another company, and its recent poor financial performance leading to a new 52-week low, might have influenced investor sentiment towards riskier assets like ELV, contributing to the bearish movement.

28.00.2026 - ELV Stock was up 5.4%

• Elevance Health (ELV) saw a strong bullish movement following a positive reaction to surpassing profit expectations for Q4 2025.
• Despite a mix of results with profits exceeding expectations but revenues falling short investor confidence surged as the company focuses on affordability and platform enhancements.
• Analysts and investors found reassurance in the company's ability to outperform profit expectations and maintain a positive earnings per share outlook for 2026 amidst revenue growth challenges and margin pressures.
• The market shift may have been influenced by general sentiment towards the healthcare and insurance sectors, weighing concerns about margin risks and membership attrition against the company's profit beat and earnings forecast.

28.00.2026 - ELV Stock was up 5.1%

• ELV stock saw an upward trend driven by investors' favorable response to the company exceeding profit expectations in the fourth quarter of 2025.
• The strong performance in earnings per share, which outperformed analyst predictions, likely contributed to the optimistic market sentiment.
• Despite falling short of revenue targets, the emphasis on affordability and the earnings per share guidance of at least $25.50 for 2026 may have reassured investors about the company's future trajectory.
• Positive analyst evaluations and market outlooks appeared to have boosted investor confidence in ELV, influencing the bullish movement in the market.

15.00.2026 - ELV Stock was up 1.4%

• Insiders at Elevance Health sold a significant amount of shares, raising concerns among investors despite reasonable insider ownership.
• ELV's price target was raised, citing a slowdown in healthcare utilization growth, indicating a peak in demand.
• A reduction in stake in ELV was noted, but the company exceeded Q3 earnings expectations, maintaining a "Moderate Buy" rating.
• UnitedHealth's announcement of speeding Medicare Advantage payments for rural hospitals may have positively impacted ELV's stock, as it signals potential growth and innovation in the healthcare sector.

11.11.2025 - ELV Stock was up 6.0%

• Elevance Health (ELV) has shown a strong bullish movement in the market recently.
• The appointment of Amy W. Schulman as an independent director is being viewed positively, enhancing the company's governance and oversight capabilities.
• Analysts have adjusted the price target for ELV to $340 from $297, maintaining a Neutral rating, indicating increased confidence in the stock's potential.
• Prominent investors like David Tepper and Michael Burry have been actively investing in ELV, signaling trust in its undervaluation and future growth.
• Despite facing challenges like rising Medical Care Ratios and regulatory changes, Elevance Health's strategic actions, such as reducing its Medicare Advantage membership and utilizing its balance sheet, are setting the stage for margin recovery and expansion.

11.11.2025 - ELV Stock was up 6.9%

• Adjusting the price target to $340 from $297 and maintaining a Neutral rating could have instilled confidence in investors, leading to increased buying activity.
• The appointment of Amy W. Schulman as an independent director, known for her expertise in healthcare innovation and governance, may have signaled to the market a strategic move towards strengthening governance and oversight capabilities, positively impacting investor sentiment.
• The reaffirmation of 2025 earnings guidance at $24.70 per share in a recent SEC filing could have provided clarity and reassurance to investors, further supporting the bullish momentum in the stock.
• The focus on board refreshment strategy with diverse and independent leadership aligns with market trends towards corporate governance best practices, potentially attracting more investors to the stock.

11.11.2025 - ELV Stock was up 5.5%

• ELV experienced a strong bullish movement today.
• The appointment of Amy W. Schulman, a distinguished healthcare executive, to the company's board of directors seems to have boosted investor confidence in ELV's governance and strategic direction.
• Analysts' positive outlook on ELV, with a 'Buy' rating and a median price target of $394, further contributed to the bullish sentiment.
• ELV's focus on healthcare innovation and strategic growth initiatives align well with market trends emphasizing technology-driven approaches in the healthcare sector.

02.00.2026 - ELV Stock was up 1.0%

• ELV's stock showed a strong bullish movement recently.
• Significant new investment in ELV was made during the third quarter, reflecting confidence in the company's future prospects.
• ELV reported impressive Q3 earnings, surpassing expectations.
• Investors are keeping a close eye on ELV's performance and upcoming earnings release to assess the impact of their capital allocation strategies on shareholder returns.